Название продукции:12,15-Dioxa-2,7,9-triazaheptadecanamide, 17-amino-N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-8-oxo-, hydrochloride (1:2)
IUPAC Name:3-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-1-{4-[({2-[2-(2-aminoethoxy)ethoxy]ethyl}carbamoyl)amino]butyl}urea dihydrochloride
- CAS:1571103-88-2
- Молекулярная формула:C18H42Cl2N6O6
- Чистота:95%+
- Номер в каталоге:CM454250
- Молекулярная масса:509.47
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:1571103-88-2
- Молекулярная формула:C18H42Cl2N6O6
- Точка плавления:-
- Smiles-код:Cl.Cl.NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCN
- Плотность:
- Номер в каталоге:CM454250
- Молекулярная масса:509.47
- Точка кипения:
- Номер Mdl:MFCD29035188
- Хранение:
Column Infos
- Tenapanor
- FDA has approved XPHOZAH (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
XPHOZAH, with its unique blocking mechanism of action, acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), reducing phosphate absorption through the paracellular pathway, the primary pathway of phosphate absorption.